News & Events
FDA NEWS RELEASE
For Immediate Release: June 15, 2010
Media Inquiries: Karen Riley, 301-796-4674, email@example.com
Consumer Inquiries: 888-INFO-FDA
FDA to Communicate Safety Monitoring Activities to Consumers and Health Care Professionals
New website will contain safety reports on recently approved drugs, biologics
The U.S. Food and Drug Administration today unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics.
Summaries of FDA safety analyses on recently approved products will now be periodically prepared and posted on FDA’s website along with a brief discussion of the steps FDA is taking to address any identified safety issues.
Some side effects may not become apparent until after a medicine has been approved and becomes available to a larger, more diverse population than the patients who participated in clinical trials that supported approval. The new summaries provide a comprehensive look at safety data early in the product’s post-approval life cycle and are based on reports by manufacturers, providers, consumers and others to the FDA’s Adverse Event Reporting System (AERS) and the Vaccine Adverse Event Reporting System maintained by the FDA and the Center for Disease Control and Prevention; periodic safety information submitted to FDA by manufacturers; information contained in the medical literature; and data from ongoing drug and biologic studies.
Included in the summaries may be information on potentially serious, previously unidentified risks, if any are found during the review, as well as known adverse events that occur more often than they did during clinical studies. The summaries will also include a brief discussion of any steps FDA may be taking to address these safety issues.
Under Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), FDA is required to prepare the safety summaries within 18 months after a product’s approval or after it has been used by 10,000 patients, whichever comes later.
“Conducting systematic, comprehensive, safety reviews of recently approved drugs and biologics provides an early detection mechanism for potentially serious risks and complements the FDA’s analysis of safety data during drug development and the agency’s routine monitoring of safety information after product approval,” said Gerald Dal Pan, M.D., M.H.S., director of the Office of Surveillance and Epidemiology in the FDA’s Center for Drug Evaluation and Research.
“These summaries will provide clear and useful information in a timely manner that can be used by providers and patients to make informed decisions about an individual’s health,” said Robert Ball, M.D., M.P.H., Sc.M., director of the Office of Biostatistics and Epidemiology in the Center for Biologics Evaluation and Research.
Initial summary reports will contain information on drugs and biologics approved since September 2007, including several drugs for infections, hypertension, depression and other conditions. The summary reports will be located on an FDA Web page that was first established in 2008 to serve as a portal for drug safety information.
For more information:
- Postmarketing Drug Safety Evaluation
- Fact Sheet: FDAAA 2007 Section 915 - Enhancing FDA’s Safety Reporting on Recently Approved Therapies (PDF - 42KB)
- Medwatch: What is a Serious Adverse Event?
- Office of Surveillance and Epidemiology (OSE)